Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972668 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL12555528 | 0.85 | CASP6 (0.57) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL1020216 | 0.83 | CA1 (0.74) | CA1CA2CA9ALDH1A1NPC1 | |
| SCHEMBL30139067 | 0.83 | LMNA (0.55) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL2639424 | 0.83 | CA1 (0.71) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL5891041 | 0.83 | CASP6 (0.56) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL5891034 | 0.83 | LMNA (0.55) | CA1CA2CA9ALDH1A1HPGD | |
| SCHEMBL2626668 | 0.82 | CA1 (0.72) | CA1CA2CA9NPC1KMT2A | |
| SCHEMBL20766191 | 0.82 | CA1 (0.74) | CA1CA2CA9NPC1KMT2A | |
| SCHEMBL14419466 | 0.81 | BACE1 (0.55) | CA1CA2CA9ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023202583-A1 | FXR REGULATOR AND USE THEREOF | 北京大学 | 2023-10-26 | — | — | WO | disclosed |
| CN-116903559-A | FXR modulators and uses thereof | 北京大学 | 2023-10-20 | — | — | CN | disclosed |
| US-9814700-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814700-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | LAUREL THERAPEUTICS LTD. (CN) | 2017-02-23 | — | — | US | disclosed |
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | LAUREL THERAPEUTICS LTD. (CN) | 2017-02-23 | — | — | US | disclosed |
| US-9498466-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9498466-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-3069721-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | Nivalis Therapeutics, Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144180-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144180-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2010019903-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019910-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| US-7273863-B1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, TRPA1, TRPV5 | CA1 1001/4885CA2 153/4885CA9 2373/4885 |
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | CA1 4697/4885CA2 4299/4885CA9 4552/4885 |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | CA1 1156/4885CA2 164/4885CA9 2755/4885 |
| US-20110144180-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | CA1 4697/4885CA2 4299/4885CA9 4552/4885 |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | CA1 4697/4885CA2 4299/4885CA9 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.